CN111108102B - 吗啉基吡啶酮化合物 - Google Patents

吗啉基吡啶酮化合物 Download PDF

Info

Publication number
CN111108102B
CN111108102B CN201880060742.XA CN201880060742A CN111108102B CN 111108102 B CN111108102 B CN 111108102B CN 201880060742 A CN201880060742 A CN 201880060742A CN 111108102 B CN111108102 B CN 111108102B
Authority
CN
China
Prior art keywords
trifluoromethyl
pharmaceutically acceptable
acceptable salt
methylmorpholin
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880060742.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN111108102A (zh
Inventor
约翰·林德斯特罗姆
里卡德·福斯布罗姆
詹妮·维克兰德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sprint Bioscience AB
Original Assignee
Sprint Bioscience AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sprint Bioscience AB filed Critical Sprint Bioscience AB
Priority to CN202310448740.0A priority Critical patent/CN116462674A/zh
Priority to CN202310448700.6A priority patent/CN116444510A/zh
Publication of CN111108102A publication Critical patent/CN111108102A/zh
Application granted granted Critical
Publication of CN111108102B publication Critical patent/CN111108102B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880060742.XA 2017-08-23 2018-08-23 吗啉基吡啶酮化合物 Active CN111108102B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202310448740.0A CN116462674A (zh) 2017-08-23 2018-08-23 吗啉基吡啶酮化合物
CN202310448700.6A CN116444510A (zh) 2017-08-23 2018-08-23 吗啉基吡啶酮化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17187567 2017-08-23
EP17187567.7 2017-08-23
PCT/EP2018/072791 WO2019038390A1 (en) 2017-08-23 2018-08-23 MORPHOLINYLPYRIDONE COMPOUNDS

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202310448740.0A Division CN116462674A (zh) 2017-08-23 2018-08-23 吗啉基吡啶酮化合物
CN202310448700.6A Division CN116444510A (zh) 2017-08-23 2018-08-23 吗啉基吡啶酮化合物

Publications (2)

Publication Number Publication Date
CN111108102A CN111108102A (zh) 2020-05-05
CN111108102B true CN111108102B (zh) 2023-04-28

Family

ID=59686888

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202310448700.6A Pending CN116444510A (zh) 2017-08-23 2018-08-23 吗啉基吡啶酮化合物
CN201880060742.XA Active CN111108102B (zh) 2017-08-23 2018-08-23 吗啉基吡啶酮化合物
CN202310448740.0A Pending CN116462674A (zh) 2017-08-23 2018-08-23 吗啉基吡啶酮化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202310448700.6A Pending CN116444510A (zh) 2017-08-23 2018-08-23 吗啉基吡啶酮化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310448740.0A Pending CN116462674A (zh) 2017-08-23 2018-08-23 吗啉基吡啶酮化合物

Country Status (20)

Country Link
US (2) US11560374B2 (enExample)
EP (2) EP4056569A1 (enExample)
JP (2) JP7199736B2 (enExample)
KR (1) KR102732013B1 (enExample)
CN (3) CN116444510A (enExample)
AU (2) AU2018320419B2 (enExample)
CY (1) CY1125117T1 (enExample)
DK (1) DK3672962T3 (enExample)
ES (1) ES2910157T3 (enExample)
HR (1) HRP20220497T1 (enExample)
HU (1) HUE058661T2 (enExample)
IL (3) IL302077A (enExample)
LT (1) LT3672962T (enExample)
PL (1) PL3672962T3 (enExample)
PT (1) PT3672962T (enExample)
RS (1) RS63109B1 (enExample)
SI (1) SI3672962T1 (enExample)
SM (1) SMT202200169T1 (enExample)
TW (2) TWI803511B (enExample)
WO (1) WO2019038390A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022115543A1 (en) * 2020-11-25 2022-06-02 Deciphera Pharmaceuticals, Llc Anti-viral activity of vps34 inhibitors
CA3199995A1 (en) * 2020-11-25 2022-06-02 Daniel L. Flynn Morpholino derivatives as vsp34 inhibitors for use in the treatment of a viral infection
US12414955B2 (en) 2020-11-25 2025-09-16 Deciphera Pharmaceuticals, Llc Anti-viral activity of VPS34 inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012085244A1 (fr) * 2010-12-23 2012-06-28 Sanofi Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique
WO2015030057A1 (ja) * 2013-08-29 2015-03-05 富士フイルム株式会社 新規なモルホリン誘導体またはその塩
CN104603113A (zh) * 2012-06-22 2015-05-06 赛诺菲 包含经取代吗啉的新型2,3-二氢-1H-咪唑并{1,2-a}嘧啶-5-酮和1,2,3,4-四氢嘧啶并{1,2-a}嘧啶-6-酮衍生物、其制备及其制药用途
WO2017140843A1 (en) * 2016-02-19 2017-08-24 Sprint Bioscience Ab 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes
WO2017140841A1 (en) * 2016-02-19 2017-08-24 Sprint Bioscience Ab 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006034473A2 (en) * 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Novel pyrimidine compounds, process for their preparation and compositions containing them
WO2011058478A1 (en) * 2009-11-16 2011-05-19 Pfizer Inc. Substituted triazolopyrimidines as pde8 inhibitors
JP2014500308A (ja) 2010-12-21 2014-01-09 ノバルティス アーゲー Ｖｐｓ３４阻害剤としてのビヘテロアリール化合物
FR2969612B1 (fr) * 2010-12-23 2013-02-08 Sanofi Aventis Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique
GB201120317D0 (en) 2011-11-24 2012-01-04 Queen Mary & Westfield College Screening method
MX2016009135A (es) 2014-01-14 2016-10-05 Millennium Pharm Inc Heteroarilos y usos de estos.
US10202373B2 (en) 2014-01-14 2019-02-12 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012085244A1 (fr) * 2010-12-23 2012-06-28 Sanofi Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique
CN104603113A (zh) * 2012-06-22 2015-05-06 赛诺菲 包含经取代吗啉的新型2,3-二氢-1H-咪唑并{1,2-a}嘧啶-5-酮和1,2,3,4-四氢嘧啶并{1,2-a}嘧啶-6-酮衍生物、其制备及其制药用途
WO2015030057A1 (ja) * 2013-08-29 2015-03-05 富士フイルム株式会社 新規なモルホリン誘導体またはその塩
WO2017140843A1 (en) * 2016-02-19 2017-08-24 Sprint Bioscience Ab 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes
WO2017140841A1 (en) * 2016-02-19 2017-08-24 Sprint Bioscience Ab 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes

Also Published As

Publication number Publication date
SI3672962T1 (sl) 2022-06-30
RU2020110506A3 (enExample) 2022-02-22
CY1125117T1 (el) 2024-12-13
PL3672962T3 (pl) 2022-05-02
SMT202200169T1 (it) 2022-05-12
WO2019038390A1 (en) 2019-02-28
AU2023285995A1 (en) 2024-01-25
IL272815B (en) 2022-06-01
CA3073142A1 (en) 2019-02-28
ES2910157T3 (es) 2022-05-11
IL292489A (en) 2022-06-01
RU2020110506A (ru) 2021-09-23
CN111108102A (zh) 2020-05-05
HRP20220497T1 (hr) 2022-05-27
KR102732013B1 (ko) 2024-11-18
AU2018320419A1 (en) 2020-04-09
TWI803511B (zh) 2023-06-01
JP7199736B2 (ja) 2023-01-06
RS63109B1 (sr) 2022-04-29
JP2020531485A (ja) 2020-11-05
US20200361922A1 (en) 2020-11-19
KR20200044025A (ko) 2020-04-28
LT3672962T (lt) 2022-05-10
EP4056569A1 (en) 2022-09-14
US11560374B2 (en) 2023-01-24
CN116444510A (zh) 2023-07-18
HUE058661T2 (hu) 2022-09-28
PT3672962T (pt) 2022-04-12
TW202348601A (zh) 2023-12-16
CN116462674A (zh) 2023-07-21
IL292489B1 (en) 2023-05-01
EP3672962B1 (en) 2022-01-26
IL292489B2 (en) 2023-09-01
TW201912161A (zh) 2019-04-01
JP2023021268A (ja) 2023-02-10
US20230234949A1 (en) 2023-07-27
EP3672962A1 (en) 2020-07-01
AU2018320419B2 (en) 2023-09-28
DK3672962T3 (da) 2022-05-02
IL302077A (en) 2023-06-01
IL272815A (en) 2020-04-30

Similar Documents

Publication Publication Date Title
AU2021215234B2 (en) 6-Aryl-4-Morpholin-1-Ylpyridone Compounds Useful For The Treatment Of Cancer And Diabetes
CN108884067A (zh) 可用于治疗癌症和糖尿病的6-杂环基-4-吗啉-4-基吡啶-2-酮化合物
US20230234949A1 (en) Morpholinylpyridone compounds
CN111094244B (zh) 吡啶基吡啶酮化合物
CN111247144B (zh) 氮杂吲哚基吡啶酮化合物和二氮杂吲哚基吡啶酮化合物
CA3073142C (en) Morpholinylpyridone compounds
RU2803158C2 (ru) Морфолинилпиридоны
HK40079060A (en) Morpholinylpyridone compounds
HK40030345B (en) Morpholinylpyridone compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant